What is new in fungal pharmacotherapeutics?

Journal of Drugs in Dermatology

Volumn 13, Issue 4, 2014, Pages 391-395

  Routt, Ethan T ^a   Jim On, Shelbi C ^a   Zeichner, Joshua A ^a   Kircik, Leon H ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Physicians Skin Care PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; EFINACONAZOLE; ITRACONAZOLE; LULICONAZOLE; NAFTIFINE; TAVABOROLE; 4-(2,4-DICHLOROPHENYL)-1,3-DITHIOLAN-2-YLIDENE-1-IMIDAZOLYLACETONITRILE; 5-FLUORO-1,3-DIHYDRO-1-HYDROXY-2,1-BENZOXABOROLE; ALLYLAMINE; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIMICROBIAL THERAPY; ARTICLE; DRUG EFFICACY; HUMAN; ONYCHOMYCOSIS; PHARMACEUTICAL CARE; TINEA PEDIS; TOPICAL TREATMENT; ANALOGS AND DERIVATIVES; MEDICAL EDUCATION;

ALLYLAMINE; ANTIFUNGAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; EDUCATION, MEDICAL, CONTINUING; HUMANS; IMIDAZOLES; ITRACONAZOLE; ONYCHOMYCOSIS; TINEA PEDIS; TRIAZOLES;

EID: 84900554084     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. James WD, Berger TG, Elston DM. Andrew's Disease of the Skin Clinical Dermatology. 11'" Edition, Philadelphia, PA, Elsevier/Saunders, 2011.
2. Scher RK. Rich P, Pariser D. Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013; 32(suppl):S2-S4.
3. Ghannoum MD, Hajjeh RA, Scher R. A large-scale North American study of fungal isolates from nails: The frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000; 43:641-648.
4. Pariser D. The rationale for renewed attention to onychomycosis. Semin Cutan Med Surg. 2013; 32(suppl): S1
5. Elewski B, Pariser D, Rich P Scher RK. Current and Emerging Options in the Treatment of Onychomycosis. Semin Cutan Med Surg. 2013; 32:S9-12.
6. ONMEL (FDA package insert). Greensboro, NC:Merz Pharmaceuticals, LLC; 2012. Accessed 11/10/13 at http://onmel.com/wp-content/uploads/ONMEL-full- prescribing-information.pdf.
7. Elewski BE. Rich R Pollak R et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013 Apr; 68(4):600-608.
8. Tosti A. Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis. Cutis. 2013 Oct; 92(4):203-8.
9. Tatsumi Y. Nagashima M. Shibanushi T et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother. 2013 May; 57(5):2405-9.
10. Elewski BE. Efinaconazole 10% solution: a new topical antifungal therapy for onychomycosis. Expert Rev Dermatol. 2013; 8(4):347-356.
11. Jo Siu WJ, Tatsumi Y Senda H et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013 Apr; 57(4):1610-6.
12. PatelT Dhillon S. Efinaconazole: First Global Approval. Drugs. 2013; 73:1977-1983.
13. Fernando LR, Mao W, Yaremchuk A et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007; 316:1759-1761. (Pubitemid 46988553)
14. Zane LT Pollak RA. Safety and Efficacy of Tavaborone (Formerly AN 2690), a Novel Boron-based Molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. 2012 Aug.
15. Baker SJ, HuiX, Sanders V, et al. Nail Penetration of AN2690: Efficacy Coefficient and Effect of Formulation. 2006. Available at: http://www.anacor. com/pdf/ESDR-P91.pdf. Accessed 11/9/13.
16. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin. Pharmacother. 2012; 13(8): 1131-1142.
17. Hui X, Baker SJ, Wester RC, et al. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007; 96(10):2622-31.
18. Al Hasan M, Fitzgerald SM, Saoudian M, et al. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy. 2004, 2:5.
19. Havlickova B, Czaika VA, Freidrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008; 51(Suppl. 4):2-15.
20. Drake LA. Dinehart SM, Farmer ER, et al. Guidelines for care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guiedelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996; 34(2):282-286.
21. Maertens JA. History of the development of azole derivatives. Clin Microbiol Iniect. 2004; 10(Suppl 1):1-10.
22. Kosinski M, Joseph WS, Markinson B. Advances in the Treatment of Tinea Pedis. Podiatry Management. 2007 June/July; 227-242.
23. Choi TS, Solomon B, Nowakowski M, et al. Effect of naftifine on neutrophil adhesion. Skin Pharmacol. 1996; 9(3):190-6.
24. Ghannoum M, Isham N, Verma A, Plaum S, Fleischer A, Hardas B. In vitro Antifungal Activity of Naftifine Hydrochloride against Dermatophytes. Antimicrob Agents Chemother. 2013; 57(9):4369-4372.
25. Monk JR Brogden RN. Naftifine: A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1991; 42(4):659-672.
26. Stein Gold LF, Parish LC, Vlahovic X et al. Efficacy and Safety of Naftifine HCL Gel 2% in the Treatment of Interdigital and Moccasin Type Tinea Pedis: Pooled Results from Two Multicenter, Randomized, Double-Blind, Vehicle-Controlled Trials. J Drugs Dermatol. 2013; 12(8):911-918.
27. NAFTIN Gel, 2% Ipackage inserti. Greensboro, NC: Merz Pharmaceuticals, LLC; June 2013. 2. Data on file, Merz Pharmaceuticals, LLC. http://naftin.com/ wp-content/uploads/NAFTIN-Gel-2-Pl.pdf. Accessed 11/9/13
28. Del Rosso JQ, Kircik LH. OptimizingTopical AntifungalTherapy for Superficial Cutaneous Fungal Infections: Focus on Topical Naftifine for Cutaneous Der- matophytosis. J Drugs Dermatol. 2013; 12(11):S165-171.
29. Plaum S, Verma A, Fleischer A, Olayinka B. Hardas B: Detection and Relevance of Naftifine Hydrocloride in the Stratum Corneum Up to Four Weeks Following the Last Application of Naftifine Cream and Gel, 2%. J Drugs Dermatol. 2013; 12(9):1004-1008.
30. Koga H. Nanjoh Y, Makimura K et al. In vitro antifungal activities of Miconazole, a new topical imidazole. Med Mycol. 2009; 47(6):640-7.
31. Jarratt M, Jones T, Kempers S, et al. Luliconazole for the treatment of interdigital tinea pedis: a double-blind, vehicle controlled study. Cutis. 2013; 91:203-210.
32. Jones T Tavakkol A. Safety andTolerability of Luliconazole Solution, 10% in Patients with Moderate to Severe Distal Sunungual Onychomycosis. Antimicrob. Agents Chemother. 2013; 57(6):2684-9.
33. Watanabe S, Takahashi H, NishikawaT, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomized doubleblind study. Mycoses. 2007: 50:35-40. (Pubitemid 46046417)
34. Little LW. Valeant Pharmaceuticals Announces U.S. Approval of Luzu Cream, 1%. 2013 Nov. Available at: http://ir.valeant.com/investor-relations/news- releases/news-release-details/2013A'aleant-Pharmaceuticals-Announces-US- Approval-Of-Luzu-Cream-1/default.aspx. Accessed 11/19/13.